Edaravone in ALS

Exp Neurol. 2009 Jun;217(2):235-6. doi: 10.1016/j.expneurol.2009.03.001. Epub 2009 Mar 10.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Amyotrophic Lateral Sclerosis / drug therapy*
  • Amyotrophic Lateral Sclerosis / genetics
  • Amyotrophic Lateral Sclerosis / physiopathology
  • Animals
  • Antipyrine / analogs & derivatives*
  • Antipyrine / therapeutic use
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Edaravone
  • Free Radical Scavengers / therapeutic use*
  • Humans
  • Inclusion Bodies / drug effects
  • Inclusion Bodies / genetics
  • Inclusion Bodies / metabolism
  • Mice
  • Motor Neurons / drug effects
  • Motor Neurons / metabolism
  • Motor Neurons / pathology
  • Neuroglia / drug effects
  • Neuroglia / metabolism
  • Neuroglia / pathology
  • Oxidative Stress / drug effects*
  • Oxidative Stress / physiology
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase / metabolism
  • Superoxide Dismutase-1

Substances

  • Free Radical Scavengers
  • SOD1 protein, human
  • Sod1 protein, mouse
  • Superoxide Dismutase
  • Superoxide Dismutase-1
  • Edaravone
  • Antipyrine